Eli Lilly and Co (LLY)
873.68
+0.56
(+0.06%)
USD |
NYSE |
Feb 21, 16:00
873.00
-0.68
(-0.08%)
Pre-Market: 20:00
Key Stats
Price and Performance | |
---|---|
Market Cap | 784.71B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 17.90% |
Valuation | |
PE Ratio | 74.61 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 17.53 |
Price to Book Value | 55.29 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | 1.50 |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 2.371 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 24.27% |
Profile
Edit
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. |
URL | https://www.lilly.com |
Investor Relations URL | https://investor.lilly.com/ |
HQ State/Province | Indiana |
Sector | Health Care |
Industry | Pharmaceuticals |
Next Earnings Release | May. 01, 2025 |
Last Earnings Release | Feb. 06, 2025 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Feb. 14, 2025 |
Ratings
Profile
Edit
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. |
URL | https://www.lilly.com |
Investor Relations URL | https://investor.lilly.com/ |
HQ State/Province | Indiana |
Sector | Health Care |
Industry | Pharmaceuticals |
Next Earnings Release | May. 01, 2025 |
Last Earnings Release | Feb. 06, 2025 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Feb. 14, 2025 |